Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia

Leukemia and Lymphoma

Volumn 22, Issue 1-2, 1996, Pages 71-76

  Ghaddar, Habib M ^a   Pierce, Sherry ^a   Kantarjian, Hagop M ^a   Freireich, Emil J ^a   Keating, Michael J ^a   Estey, Elihu H ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myelogenous leukemia; Amsacrine; High dose cytarabine

Indexed keywords

AMSACRINE; ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MYCOSIS; PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029995507     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609051730     Document Type: Article

References (23)

1. Ellison, R. R., Holland, J. F., Weil, M., Jacquillat, C., Boiron, M., Bernard, J., Sawitsky, A., Rosner, F., Gussoff, B., Silver, R. T., Karanas, A., Cuttner, J., Spurr, C. L., Hayes, D. M., Blom, J., Leone, L. A., Haurani, F., Kyle, R., Hutchinson, J. L., Forcier, R. J. and Moon J. H. (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood, 32, 507-523.
2. Keating MJ, McCredie, K. B., Bodey, G. P., Smith, T. L., Gehan, E. and Freireich, E. J. (1982) Improved prospects for long term survival in adults with acute myelogenous leukemia. JAMA, 248, 2481-2486.
3. Gale, R. P. and Cline, M. J. (1977) High remission induction rate in acute myeloid leukemia. Lancet, 1, 497-499.
4. Yates, J. W., Wallace, H. J., Ellison, R. R. and Holland, J. F. (1973) Cytosine arabinoside (NSC-638781 and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Treat. Rep.. 57, 485-488.
5. Keating, M., Gehan, E., Smith, T., Estey, E. H., Walters, R. S., Kantarjian, H. M., McCredie, K. B. and Freireich, E. J. (1987) A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J. Clin. Oncol, 5, 710-721.
6. Cassileth, P. A. and Katz, M. E. (1977) Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cy tosine arabinoside. Cancer Treat. Rep., 61, 1441-1445.
7. Yates, J., Glidewell, O., Wilernik, P. and Cooper, M. R. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 60, 454-462.
8. Ghaddar, H., Plunkett, W., Kantarjian, R. Pierce, S., Freireich, E., Keating, M. and Estey, E. (1994) Long term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion cytosine arabinoside. Leukemia, 8, 1269-1274.
9. Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H. and Keating, M. J. (1987) Saturation of 1 - D-arabinofuranosylcytosine 5¢-triphosphate accumulation in leukemic cells during high-dose 1 - D-arabinofuranosylcytosine therapy. Cancer Res., 47, 3005-3011.
10. Heinemann, V., Estey, E., Keating, M. J. and Plunkett, W. (1989) Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J. Clin. Oncol., 7, 622-628.
11. Kessel, D. and Hall, T. C. (1967) Transport and phosphorylation as factors in antitumor action of cytosine arabinoside. Science, 156, 1240-1241.
12. Kufe, D. W., Spriggs, D., Egan, E. M. and Munroe, D. (1984) Relationship among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood, 64, 54-58.
13. Legha, S. S., Keating, M. J., McCredie, K. B., Bodey, G. P. and Freireich, E. J. (1982) Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults. Blood, 60, 484-490.
14. Breman, E., Arlin, Z.A., Gaynor, J., Miller, W., Gee, T. and Kempin, S. J. (1989) Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. Leukemia, 3, 115-121.
15. Arlin, Z. A., Ahmed, T., Mittelman, A., Feldman, E., Mehta, R. and Weinstein, P. (1987) A new regimen with high-dose cytarabine is safe and effective therapy for acute leukemia. J. Clin. Oncol., 5, 371-375.
16. Arlin, Z. A., Feldman, E. J., Mittelman, A., Ahmed. T., Puccio, C. and Chun, H. G. (1991) Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer, 68, 1198-1200.
17. Watson, A. M., Seymour, J., Lee, N., Whiteside, M. and Firkin, F. (1994) An effective age-unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukaemia. Eur. J. Haematol., 52, 80-86.
18. Jehn, U. and Heinemann, V. (1993) Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine. Ann Hematol, 66, 131-134.
19. Estey, E., Smith, T. L., Keating M. J, McCredie, K. B., Gehan, E. A. and Freireich, E. J. (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myelogenous leukemia. Leukemia, 3, 257-263.
20. Keating, M. J., Smith, T. L., Kantarjian, H., Cork, A., Walters, R., Trujillo, J. M., McCredie, K. B., Gehan, E. A. and Freireich, E. J. (1988)Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia, 2, 403-412.
21. Bloomfield, C. (1992) Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia, 6 (4 suppl), 65-67.
22. Bloomfield, C. D., Lawrence, D., Arthur, D.C., Berg, D.T., Schiffer, C. A. and Mayer, R. J. (1994) Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood, 84 (suppl 1), 111a.
23. Avvisati, G., Mandelli, F., Petti, M. C. Vegna, M. L., Spadea, A., Liso, V., Specchia, G., Bernasconi, C. Alessandrino, E. P., Piatti, C. and Carella, A. M. (1990) Idarubicin(4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian Cooperative Group GIMENA. Eur. J. Haematol., 44, 257-260.